Skip to main content
. Author manuscript; available in PMC: 2022 Nov 20.
Published in final edited form as: Free Radic Biol Med. 2021 Sep 20;176:92–104. doi: 10.1016/j.freeradbiomed.2021.09.013

Figure 4.

Figure 4.

Application of the mitochondria-permeable iron chelator Deferiprone (DFP) suppresses mitochondrial labile iron (mLI) and mirochondrial ROS (mROS) accumulation but has no effect on changes in ER and cytosolic calcium levels. A. Application of DFP suppresses the accumulation of mLI levels in DOX (2μg/ml; 48 hour)-treated H114C cells. B. Application of DFP suppresses the accumulation of mROS levels in DOX (2μg/ml; 48 hour)-treated H114C cells. C. Application of DFP does not affect the decrease in cytosolic calcium levels in DOX (2μg/ml; 72 hour)-treated H114C cells. D. Application of DFP does not affect the increase in ER calcium levels in DOX (2μg/ml; 72 hour)-treated H114C cells. Results are shown as mean ± SE of 6, 7 or 12 biological control averages, each conducted with 3 technical repeats. N=6 for (A), N=7 for (B), and N=12 for (C and D); two-way ANOVA followed by a Tukey test; ns, not significant.